Skip to main content

CAR.70/IL15-transduced CB-NK cells

CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

  • RegistryNCT05092451
  • PhasePhase 1/2
  • StatusRecruiting
  • ConditionB-Cell Lymphoma
  • SponsorM.D. Anderson Cancer Center
How CAR.70/IL15-transduced CB-NK cells worksNCT050924511 min

What the film says

Read the transcript

CAR T cells have cured some blood cancers. But they must be built from each patient's own blood, over weeks, and a relapsed patient may not have weeks.

The idea: build the cells in advance, from umbilical cord blood, so they wait in the freezer.

Natural killer cells from donated cord blood are given a receptor for CD70, a protein on many leukemias, lymphomas, and myelomas but few healthy cells. They also carry a gene for interleukin-15, a survival signal, so they persist. In myeloma models, they kept working after the usual target, BCMA, disappeared.

MD Anderson, with David Marin, gives one dose after chemotherapy makes room, to patients from age twelve whose cancer carries CD70. Safety first. Public record; not medical advice.

Sources behind this film

The drug

What is being tested.

Primary Objective: To determine the safety, efficacy and optimal cell dose of CAR.70/IL15-transduced CB-NK cells in patients with relapsed/refractory hematological malignances. The efficacy and optimal dose will be identified for individual diseases. Secondary Objectives: * To quantify persistence of infused allogeneic donor CAR-transduced CB-derived NK cells in the recipient. * To conduct comprehensive immune reconstitution studies.

The study

How the trial runs.

The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells. Researchers think that NK cells you receive from a donor may react against cancer cells in your body, which may help to control the disease.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Patients with hematological malignances with an expression of CD70 in the pre-enrollment tumor sample ≥ 10% measured by immunohistochemistry or flow cytometry.
  • Patients must meet diseases specific eligibility criteria (see below)
  • Patients at least 1 week from last cytotoxic chemotherapy at the time of starting lymphodepleting chemotherapy, except for Hydroxyurea which is allowed for peripheral blood count control in AML, CML, and MDS patients until the day prior to administration of lymphodepleting chemotherapy. Patients may continue tyrosine kinase inhibitors or other targeted therapies until up to three days prior to administration of lymphodepleting chemotherapy.
  • Localized radiotherapy to one or more disease sites is allowed prior the infusion provided that there are additional disease sites that are not irradiated to assess response
  • Karnofsky Performance Scale > 50% for patients who are >16 years old or Lansky score ≥50% for patients who are ≤16 years of age.
  • Adequate organ function:

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.